https://orcid.org/0000-0002-0745-8722
References
- Moore JE, Mastoridis P. Clinical implications of Pseudomonas aeruginosa location in the lungs of patients with cystic fibrosis. J Clin Pharm Ther. 2017;42:259–267.
- Françoise A, Héry-Arnaud G. The microbiome in cystic fibrosis pulmonary disease. Genes (Basel). 2020;11:536.
- Anon. UK cystic fibrosis registry annual data report 2018. [cited 2 July 2020]. Available from: www.cysticfibrosis.org.uk
- Nagano Y, Elborn JS, Millar BC, et al. Comparison of techniques to examine the diversity of fungi in adult patients with cystic fibrosis. Med Mycol. 2010;48:166–176.
- Anon. Clinical laboratory standards institute (CLSI). M100. Performance Standards for Antimicrobial Susceptibility Testing. [cited 2020 June 26]. Available from: https://clsi.org/standards/products/microbiology/documents/m100/
- Fourie R, Pohl CH. Beyond antagonism: the interaction between Candida species and Pseudomonas aeruginosa. J Fungi. 2019;5:34.
- Azoulay E, Timsit JF, Tafflet M, et al. Candida colonization of the respiratory tract and subsequent Pseudomonas ventilator-associated pneumonia. Chest. 2006;129:110–117.
- Mear JB, Gosset P, Kipnis E, et al. Candida albicans airway exposure primes the lung innate immune response against Pseudomonas aeruginosa infection through innate lymphoid cell recruitment and interleukin-22-associated mucosal response. Infect Immun. 2014;82:306–315.
- Bergeron AC, Seman BG, Hammond JH, et al. Candida albicans and Pseudomonas aeruginosa interact to enhance virulence of mucosal infection in transparent Zebrafish. Infect Immun. 2017;85:e00475–17.